Clinical trials
HBV (Hepatitis B Virus) clinical trials
Below are recruiting hbv (hepatitis b virus) clinical trials, each written for real people, not researchers. We’re tracking 68 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06887036RecruitingPhase 2
Methylene blue for chronic inactive hepatitis B
This trial tests whether a medication called methylene blue can help lower the amount of hepatitis B virus in people with a chronic but inactive infection. It may be an option for people whose virus levels are stable but not fully controlled.
Lugano, Canton TicinoAges 18–79 - NCT06876467Recruiting
Study of immune response to hepatitis B vaccine
This study looks at how your body's cells respond after getting a hepatitis B vaccine. It may help researchers understand how well the vaccine works.
ParisAges 18 years+ - NCT06853886Recruiting
Genetic study for hepatitis B patients to find new treatment pathways
This study looks at the genes of people with chronic hepatitis B (HBV) to find why some people's immune cells (B cells and NK cells) stop working properly. The goal is to discover new ways to treat the disease.
LimogesAges 18 years+ - NCT06680232RecruitingPhase 1
Gene therapy trial for chronic hepatitis B
This trial tests a gene therapy called PBGENE-HBV for people with chronic hepatitis B who are already on antiviral treatment. The goal is to see if it is safe and can help control the virus.
Boston, MassachusettsAges 18–70 - NCT06513286RecruitingPhase 1/Phase 2
Therapeutic hepatitis B vaccine study using a two-part shot
This trial tests a new vaccine to treat chronic hepatitis B. It's for people who have been on antiviral medication for at least 6 months and still have a low level of the virus in their blood.
FrankfurtAges 18–70 - NCT04843852RecruitingPhase 1
Test vaccine added to hepatitis B treatment
This early-phase study tests whether a hepatitis B vaccine (with an added ingredient to boost the immune response) can safely help people with long-term hepatitis B who are already on antiviral therapy. It is mainly looking at safety and how the immune system responds.
Baltimore, MarylandAges 18 years+ - NCT05769816RecruitingPhase 2
Combination treatment aimed to cure chronic hepatitis B
This Phase 2 study tests a combination therapy to help people with chronic hepatitis B reach a “functional cure,” meaning the hepatitis B surface antigen (HBsAg) is lost for a sustained period. If you qualify, you’ll be closely monitored to see how well the treatment works and whether it’s safe for you.
Chongqing, Chongqing MunicipalityAges 18–70 - NCT05771402RecruitingPhase 2
Combination treatment aimed at clearing hepatitis B long-term
This Phase 2 study tests a combination treatment to help people with chronic hepatitis B stop having detectable hepatitis B surface antigen (called HBsAg). If successful, it may move you closer to a “functional cure,” meaning lower ongoing virus activity over time.
Chongqing, Chongqing MunicipalityAges 18–70 - NCT07709520RecruitingPhase 2
Testing a new hepatitis B treatment in adults
This trial tests a new treatment (GST-HG131&141 tablets) versus a placebo for people with chronic hepatitis B. It aims to see if the treatment can better control the virus in those already on stable therapy.
BeijingAges 35–65 - NCT07635186RecruitingPhase 2
AHB-137 injection for treatment-naïve chronic hepatitis B
This study tests a new injection called AHB-137 in people with chronic hepatitis B who have never received antiviral treatment. The goal is to see if it can help reduce the hepatitis B virus in the body and improve liver health.
Beijing, Beijing MunicipalityAges 18–65 - NCT06295328RecruitingPhase 1/Phase 2
Terbinafine for chronic hepatitis B: safety and effect
This study tests whether a fungus-fighting drug, terbinafine, can help treat chronic hepatitis B. It is for people with stable disease who are not on other antivirals or are only on tenofovir.
Amsterdam, North HollandAges 18–60 - NCT07307586RecruitingPhase 3
Azvudine for new hepatitis B patients
This study tests a new pill (azvudine) to see if it can cure chronic hepatitis B in people who have never been treated before. It is for those with active infection and elevated liver enzymes.
Zhengzhou, HenanAges 18–65 - NCT05182463RecruitingPhase 4
Peginterferon test for inactive chronic hepatitis B
This trial studies whether pegylated interferon can help people with inactive chronic hepatitis B stay stable or improve outcomes. You may qualify if your virus levels and liver blood tests are currently low and you’ve never used antiviral treatments.
Guangzhou, GuangdongAges 18–60 - NCT06154278RecruitingPhase 2
Testing imdusiran for chronic hepatitis B
This trial tests an injected medication called imdusiran (AB-729) to see how it affects the immune system in people with chronic hepatitis B. It is for people who are already stable on oral antivirals and want to try a new approach to possibly control the virus better.
Baltimore, MarylandAges 18 years+ - NCT07413549RecruitingPhase 1/Phase 2
Stem cell injection for hepatitis B cirrhosis
This trial tests an injection of stem cells from donated umbilical cords to see if it can help people with advanced liver scarring from hepatitis B. You may be able to join if standard treatments haven’t helped enough and you aren’t able to get a liver transplant.
WuhanAges 18–75 - NCT06216470RecruitingPhase 2
Testing an antibody treatment for chronic hepatitis B
This study tests a new antibody treatment (VIR-3434) for chronic hepatitis B. It aims to see if the antibody can help your immune system control the virus, potentially allowing you to stop your current antiviral medication later.
Toronto, OntarioAges 18–65 - NCT04231565Recruiting
Testing antiviral medicines for hepatitis B with normal liver blood tests
This trial studies how well nucleoside (nucleoside-acid) type antiviral medicines control hepatitis B in people whose liver enzyme test (ALT) is currently normal. It may help those with active hepatitis B but no major liver inflammation on recent bloodwork.
Guangzhou, GuangdongAges 18–65 - NCT06668727RecruitingPhase 1
Testing a new antibody for hepatitis B safety
This trial tests an experimental antibody treatment for people with chronic hepatitis B who have been on antiviral medication for at least 6 months. It aims to see if the antibody is safe and can help control the virus.
Aarhus NAges 18–70 - NCT07449091Recruiting
HBV undetectable equals untransmissible study
This study checks if having undetectable hepatitis B virus (HBV) means you cannot pass it to others. It tests this idea in people with chronic HBV who are on treatment, those not on treatment, and healthy controls.
New York, New YorkAges 18–65 - NCT07370207RecruitingPhase 2
Study of AHB-137 for HBeAg negative chronic hepatitis B
This study tests a new medicine called AHB-137 for people with chronic hepatitis B who are HBeAg negative and currently on antiviral therapy. The goal is to see if it can help control the virus better or allow you to stop your current medication safely.
Fitzroy, VictoriaAges 18–65 - NCT03920618Recruiting
Testing three HBV medicines for severe liver flare (ACLF)
This study compares three hepatitis B (HBV) medicines to see which treatment helps people with a severe liver flare. You may be eligible if you have confirmed HBV and lab results showing significant liver stress.
Guangzhou, GuangdongAges 12–65 - NCT04597164Recruiting
Test a hepatitis B–targeted treatment for serious liver failure
This trial studies a combination approach called DPMAS and low-volume plasma exchange for people with hepatitis B–related acute-on-chronic liver failure. If you qualify, the goal is to improve your liver function and reduce serious complications from liver failure.
Guangzhou, GuangdongAges 18–65 - NCT05988879Recruiting
Functional cure for hepatitis B in HIV/HBV co-infection
This trial tests whether people with both HIV and hepatitis B can achieve a functional cure for hepatitis B. It aims to see if current treatment can be stopped safely after the hepatitis B virus is no longer active.
Guangzhou, GuangdongAges 18–65 - NCT06047093Recruiting
Study of Hepatitis B Virus in the Liver
This study collects a small sample of liver cells to understand how hepatitis B virus behaves in the liver and how the immune system responds. This could help improve future treatments for chronic hepatitis B.
LyonAges 18 years+
Hear when a new HBV (Hepatitis B Virus) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for hbv (hepatitis b virus)?
- Yes. Clin2 currently lists 68 recruiting hbv (hepatitis b virus) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a hbv (hepatitis b virus) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a hbv (hepatitis b virus) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.